<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; scandalizing</title>
	<atom:link href="http://www.tapanray.in/tag/scandalizing/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>An Emerging Yo-Yo Syndrome With Biosimilar Drugs</title>
		<link>http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-emerging-yo-yo-syndrome-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 18 Jul 2016 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Adalimumab]]></category>
		<category><![CDATA[Affordable Care Act]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[hurdle]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scandalizing]]></category>
		<category><![CDATA[Shield]]></category>
		<category><![CDATA[Syndrome]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yo-Yo]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7727</guid>
		<description><![CDATA[Competition from Biosimilar drugs poses a threat of a combined revenue loss of estimated US$ 110 billion of those pharma players who are still enjoying market monopoly with patented biologic brands. This is expected to surely happen, in the long &#8230; <a href="http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Scandalizing Biosimilar Drugs With Safety Concerns</title>
		<link>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scandalizing-biosimilar-drugs-with-safety-concerns</link>
		<comments>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/#comments</comments>
		<pubDate>Mon, 25 Aug 2014 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12]]></category>
		<category><![CDATA[badmouthing]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GPhA]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scandalizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Year]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5772</guid>
		<description><![CDATA[With the patent expiry of exorbitantly priced biologic medicines, introduction of biosimilar drugs are expected to improve their access to millions of patients across the world, saving billions of dollars in healthcare costs in the subsequent years. According to an &#8230; <a href="http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
